![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sumitomo to Transfer Antitumor Antibiotic Sales to Nippon Kayaku
Sumitomo to Transfer Antitumor Antibiotic Sales to Nippon Kayaku
February 21, 2005
Sumitomo Pharmaceuticals has announced that it has signed a memorandum to transfer sales of its proprietary antitumor drug Calsed to Nippon Kayaku. In addition, the two companies will collaborate in post-marketing surveillance studies. Calsed, an anthracycline antitumor agent, has been widely used in the treatments of small-cell and non-small-cell lung cancers since its release in December 2002.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9186)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct